What Are the Three Newest Drugs for Arthritis Pain Relief?
Discover the latest arthritis pain treatments: Upadacitinib, Tofacitinib, and Baricitinib, effective JAK inhibitors to reduce inflammation and pain.
128 views
Three of the newest drugs for arthritis pain include: Upadacitinib (Rinvoq), Tofacitinib (Xeljanz), and Baricitinib (Olumiant). These medications are part of a new class of treatments known as Janus kinase (JAK) inhibitors, which help reduce inflammation and pain in arthritis patients.
FAQs & Answers
- What are JAK inhibitors and how do they work for arthritis? JAK inhibitors are a class of medications that block Janus kinase enzymes, which play a role in the inflammatory process. By inhibiting these enzymes, the drugs reduce inflammation and pain in arthritis patients.
- Are Upadacitinib, Tofacitinib, and Baricitinib safe for long-term use? These drugs have been approved by health authorities for arthritis treatment, but long-term safety depends on individual patient factors and should be monitored by a healthcare provider.
- How do the newest arthritis drugs compare to traditional treatments? Newer JAK inhibitors often provide targeted action against inflammation with oral administration, offering an alternative to traditional therapies like NSAIDs or injectable biologics.